Generate Biomedicines, Inc. GENB
- Market cap
- $2.1B
- P/E
- 0.0×
Follow GENB
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | — |
Analyst estimates 2026–2028 Powerpack |
Low Price | ||
| — | — | — | — | — | — | — | — | — | — | High Price | |||
| — | — | — | — | — | — | — | — | — | 312 |
Employees
|
|||
| — | — | — | — | — | — | — | — | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | — | — | — | — | — | 20 | 32 |
Revenue
|
|||
| — | — | — | — | — | — | — | — | 100.00% | 100.00% |
Gross Margin
|
|||
| — | — | — | — | — | — | — | — | (181) | (223) |
EBT
|
|||
| — | — | — | — | — | — | — | — | (885.54%) | (698.59%) |
EBT Margin
|
|||
| — | — | — | — | — | — | — | — | (181) | (223) |
Net Income
|
|||
| — | — | — | — | — | — | — | — | 10 | 10 |
Depreciation
|
|||
| — | — | — | — | — | — | — | — | 0.64 | 0.97 |
Revenue/Sh
|
|||
| — | — | — | — | — | — | — | — | (5.65) | (6.76) |
Earnings/Sh
|
|||
| — | — | — | — | — | — | — | — | (3.67) | (6.08) |
Cash Flow/Sh
|
|||
| — | — | — | — | — | — | — | — | (0.11) | (0.11) |
Capex/Sh
|
|||
| — | — | — | — | — | — | — | — | (3.78) | (6.19) |
Free CF/Sh
|
|||
| — | — | — | — | — | — | — | — | (13.54) | (18.68) |
Book Value/Sh
|
|||
| — | — | — | — | — | — | — | — | 32 | 33 |
Shares
|
|||
| — | — | — | — | — | — | — | — | 0.00 | 0.00 |
PE Ratio
|
|||
| — | — | — | — | — | — | — | — | 0.00 | 0.00 |
PS Ratio
|
|||
| — | — | — | — | — | — | — | — | 0.00 | 0.00 |
PB Ratio
|
|||
| — | — | — | — | — | — | — | — | 0.00 | 0.00 |
EV/Sales
|
|||
| — | — | — | — | — | — | — | — | (0.46) | (0.46) |
EV/FCF
|
|||
| — | — | — | — | — | — | — | — | (118) | (201) |
Op' Cash Flow
|
|||
| — | — | — | — | — | — | — | — | (3) | (4) |
Capex
|
|||
| — | — | — | — | — | — | — | — | (121) | (204) |
FCF
|
|||
| — | — | — | — | — | — | — | — | 321 | 152 |
Working Cap'
|
|||
| — | — | — | — | — | — | — | — | 6 | 3 |
Total Debt
|
|||
| — | — | — | — | — | — | — | — | (389) | (219) |
Net Debt
|
|||
| — | — | — | — | — | — | — | — | (435) | (616) |
Sh' Equity
|
|||
| — | — | — | — | — | — | — | — | 0.00% | (58.82%) |
ROA
|
|||
| — | — | — | — | — | — | — | — | 0.00% | 0.00% |
ROIC
|
|||
| — | — | — | — | — | — | — | — | 0.00% | 47.51% |
ROE
|
|||
Generate Biomedicines, Inc. (GENB) key facts
- Generate Biomedicines, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $31.9 million, up 55.9% from fiscal 2024.
- As of September 25, 2026, GENB traded at $15.15, a market capitalization of $2.1 billion.
- Return on equity was 47.5% and debt-to-equity 0.00.
Generate Biomedicines, Inc. (GENB) Latest News
6 Aug
Generate Biomedicines Inc. reported second quarter 2026 financial results and issued a business update. Quarterly financial results and business updates typically produce moderate effects on valuation and short-term market sentiment.
5 Aug
Nvidia CEO Jensen Huang names Generate Biomedicines his favorite biotech stock. High-profile endorsement from Nvidia CEO can drive investor interest and positively affect Generate Biomedicines market valuation.
11 Jul
Nvidia CEO Jensen Huang stated AI will have its most profound impact in life sciences and backed Generate Biomedicines, Inc. (GENB) with an investment, prompting questions on whether this validates the company's AI-driven approach. Nvidia CEO's endorsement paired with direct investment in Generate Biomedicines signals major external validation likely to lift market sentiment and valuation.
23 Jun
Flagship Pioneering and Lean Business Services Company announce collaboration to advance healthcare innovation and AI-enabled biomedical research in Saudi Arabia. Collaboration expands AI-biomedical research opportunities for Flagship-backed Generate Biomedicines in new markets.
20 May
Generate Biomedicines, Inc. received a $10.4 million investment from Nvidia. Nvidia's $10.4 million investment validates Generate Biomedicines' AI drug platform and strengthens its competitive position in biotech.
7 May
Generate Biomedicines, Inc. reported first quarter 2026 financial results and provided a business update. Quarterly financial results and business updates deliver performance data that can shift market views but rarely redefine company trajectory outright.
19 Apr
H.C. Wainwright initiates coverage of Generate Biomedicines (GENB) with a Buy rating. Buy rating initiation by a major firm can moderately lift near-term investor sentiment for GENB.
26 Feb
Generate Biomedicines, Inc. announced the pricing of its initial public offering. IPO pricing sets initial valuation and enables public trading which directly shapes near-term market performance.